Genomic screening encourages people with hemochromatosis to seek treatment and relevant management

Genomic screening to identify hemochromatosis-;a disorder that causes iron levels in the body to rise to dangerous levels-;encourages people with the condition to seek treatment and ongoing management, a Geisinger study found.

Hereditary hemochromatosis type 1 (HH1), caused by a change in the HFE gene, is underdiagnosed, often resulting in missed opportunities for early and consistent treatment. Without treatment, hemochromatosis can cause iron overload, a buildup of iron that can damage many parts of the body. Treatment of hemochromatosis includes regular monitoring of iron levels and removing excess iron from the body.

The Geisinger study evaluated genetic and electronic health record data for 86,601 participants enrolled in the MyCode Community Health Initiative. Of this group, 201 were found to have changes in the HFE gene, but only 28% of these had been previously diagnosed with HH1. Of those who were notified about their genetic change through MyCode, 69% proceeded with a recommended lab test, and 69% of those whose labs showed evidence of iron overload began subsequent treatment.

Historically, people have been found to have hemochromatosis due to a personal or family history. We found that genetic screening for HFE across a healthcare population identifies underdiagnosed iron overload, encourages relevant management and offers the potential to reduce morbidity and mortality associated with iron overload."

Juliann Savatt, MS, CGC, assistant professor and co-director of the MyCode Genomic Screening and Counseling Program at Geisinger

The results were published Oct. 23 in JAMA Network Open.

More research is needed to determine the long-term impact of genomic screening on health outcomes and cost-effectiveness for those with hemochromatosis, the study team wrote.

Source:
Journal reference:

Savatt, J. M., et al. (2023). Testing and Management of Iron Overload After Genetic Screening–Identified Hemochromatosis. JAMA Network Open. doi.org/10.1001/jamanetworkopen.2023.38995.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer